




Instance: composition-en-249170621fe2e34bc97c331b03b5b5b0
InstanceOf: CompositionUvEpi
Title: "Composition for poteligeo Package Leaflet"
Description:  "Composition for poteligeo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7761089c74a9dfa81323fc8f18a36e0c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - poteligeo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What POTELIGEO is and what it is used for  </li>
<li>What you need to know before you use POTELIGEO </li>
<li>How POTELIGEO is given </li>
<li>Possible side effects  </li>
<li>How to store POTELIGEO  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What poteligeo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What poteligeo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>POTELIGEO contains the active substance mogamulizumab, which belongs to a group of medicines 
called monoclonal antibodies. Mogamulizumab targets cancer cells which are then destroyed by the 
immune system (the body s defence). </p>
<p>This medicine is used to treat adults with mycosis fungoides and S zary syndrome, which are types of 
cancers called cutaneous T-cell lymphomas.  The medicine is for use in patients who have received at 
least one medicine given by mouth or by injection. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take poteligeo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take poteligeo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use POTELIGEO:</p>
<ul>
<li>if you are allergic to mogamulizumab or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor or nurse before using POTELIGEO if you:</p>
<ul>
<li>ever had a severe skin reaction with this medicine. </li>
<li>ever had an infusion reaction with this medicine (possible symptoms of an infusion reaction are 
listed in section 4). </li>
<li>have human immunodeficiency virus (HIV), herpes, cytomegalovirus (CMV), or hepatitis B or 
C infection, or other on-going infections.  </li>
<li>have had or plan to have a stem cell transplant, either using your own cells or a donor s.  </li>
<li>have had tumour lysis syndrome (a complication involving the destruction of cancer cells) after 
a previous treatment. </li>
<li>have heart problems. </li>
</ul>
<p>Tell the person giving you the infusion or get medical help straight away if you experience a 
reaction during or after any POTELIGEO infusion. </p>
<p>Tell your doctor immediately if you experience any of the serious side effects listed in Section 4 
after starting POTELIGEO treatment. </p>
<p>Other medicines and POTELIGEO 
Tell your doctor if you are taking, have recently taken,or might take any other medicines. </p>
<p>Children and adolescents 
This medicine should not be used in children and adolescents below 18 years of age. </p>
<p>Pregnancy and breast-feeding 
The effects of POTELIGEO in pregnancy and breast-feeding are not known. Due to the mechanism of 
action of the medicine, it may harm your baby if it is administered when you are pregnant or 
breast- feeding. </p>
<p>If you can get pregnant, you will need to use effective contraception during and for at least six months 
after receiving this treatment. </p>
<p>If you are breast-feeding, you should discuss with your doctor whether you can breast-feed during or 
after treatment with POTELIGEO. </p>
<p>You must tell your doctor or nurse if you are pregnant, breast-feeding, think you may be pregnant, or 
are planning to have a baby.  </p>
<p>Driving and using machines 
POTELIGEO is unlikely to affect your ability to drive and use machines. However, the medicine can 
cause tiredness in some people, so take particular care when driving and using machines until you are 
certain that this medicine does not affect you.  </p>
<p>POTELIGEO contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take poteligeo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take poteligeo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The amount of POTELIGEO you will receive is calculated by your doctor based on your body weight.<br />
The recommended dose is 1mg POTELIGEO for each kg of body weight. </p>
<p>POTELIGEO will be given to you through a vein (intravenous infusion) over at least 60 minutes. To 
start with, the infusions will be given once a week for the first 5 doses, then once every 2 weeks. 
Treatment should be continued unless you get serious side effects or the cutaneous T-cell lymphoma 
starts to get worse.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects </p>
<p>Tell your doctor or nurse or get medical help immediately if you have any of the following signs 
and symptoms after starting POTELIGEO: </p>
<p>Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>chills, nausea or vomiting, headache, wheezing, itching, flushing, rash, dizziness or feeling 
faint, difficulty breathing and fever, which may be signs of an infusion reaction. If this happens, 
the infusion may need to be stopped and you may require additional treatment. When the 
symptoms go away, POTELIGEO can normally continue to be given, but more slowly. Your 
doctor may stop POTELIGEO treatment if your reaction is severe.  </li>
<li>signs of infection, which may include a fever, sweats or chills, flu-like symptoms, sore throat or 
difficulty swallowing, cough, shortness of breath, stomach pain, nausea or vomiting, diarrhoea 
and feeling very unwell.  </li>
<li>
<p>skin rash (which may become severe), or sore mouth. In some people receiving POTELIGEO 
for other types of cancers, skin pain/burning sensation, itching, skin blisters/peeling, ulcers in 
the mouth or on the lips or genitals occurred, which are possible signs of a severe skin reaction, 
such as Stevens-Johnson syndrome or toxic epidermal necrolysis (which affected up to 1 in people).<br />
Uncommon side effects (may affect up to 1 in 100 people):</p>
</li>
<li>
<p>fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark 
or cloudy urine, unusual tiredness and/or muscle or joint pain. The destruction of cancer cells 
and the body s reaction to it can very occasionally lead to a problem called tumour lysis 
syndrome. </p>
</li>
<li>
<p>chest pain, shortness of breath, fast or slow heartbeat, sweating, dizziness, nausea or vomiting, 
weakness, feeling faint and feeling unwell. Although unlikely to be caused by this medicine, 
these may be signs of a heart disorder. 
Not known (frequency cannot be estimated from the available data):</p>
</li>
<li>
<p>if you go on to have a stem cell transplant, it is possible that you could then develop 
complications (graft versus host disease) that are difficult to manage. Symptoms may include 
skin rashes or blistering, nausea or diarrhoea that doesn t go away, stomach pain or vomiting, 
joint pain or stiffness, dry or irritated eyes or blurred vision, mouth sores, irritation or pain, a 
cough that does not go away or difficulty breathing, sensitive genitals, jaundice (turning 
yellow), dark urine, and any swelling. </p>
</li>
</ul>
<p>Other side effects </p>
<p>Talk to your doctor if you get any other side effects. These can include: </p>
<p>Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>Lack of energy (fatigue) </li>
<li>Constipation </li>
<li>Swollen legs or ankles  </li>
<li>Headache </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>Anaemia (reduced red blood cells) </li>
<li>Reduced blood platelets (thrombocytopenia) </li>
<li>Reduced white blood cells (neutropenia and leucopenia) or reduced lymphocytes </li>
<li>Blood tests showing raised liver enzyme levels </li>
<li>Underactive thyroid </li>
</ul>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
- Inflammation of the liver (hepatitis) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects, you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store poteligeo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store poteligeo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the vial after  EXP . 
The expiry date refers to the last day of that month. </p>
<p>Unopened vial: Store in a refrigerator (2 C - 8 C). Do not freeze. </p>
<p>Store in the original carton in order to protect from light </p>
<p>Reconstituted/diluted solution: Use immediately or store in a refrigerator (2 C - 8 C) and use within 
24 hours. </p>
<p>Do not use this medicine if you notice signs of deterioration, such as particulate matter or 
discolouration.  </p>
<p>Do not throw away any medicines via wastewater or household waste. These measures will help 
protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What POTELIGEO contains 
- Each vial contains 20 mg of mogamulizumab in 5 mL of concentrate, corresponding to 
4 mg/mL. 
- The other excipients are citric acid monohydrate, glycine, polysorbate 80, sodium hydroxide, 
hydrochloric acid, and water for injections. See section 2  POTELIGEO contains sodium . </p>
<p>What POTELIGEO looks like and contents of the pack 
POTELIGEO is a clear, colourless solution. The pack contains a glass vial containing 5 mL 
concentrate for solution for infusion.  </p>
<p>Marketing Authorisation Holder 
Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132NP Hoofddorp 
Netherlands  </p>
<p>Manufacturer<br />
allphamed PHARBIL Arzneimittel GmbH 
Hildebrandstr. 10-37081 G ttingen 
Germany </p>
<p>This leaflet was last revised in &lt;{MM/YYYY}&gt;&lt;{month YYYY}&gt;. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-249170621fe2e34bc97c331b03b5b5b0
InstanceOf: CompositionUvEpi
Title: "Composition for poteligeo Package Leaflet"
Description:  "Composition for poteligeo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7761089c74a9dfa81323fc8f18a36e0c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - poteligeo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at bruge POTELIGEO 
3. Sådan gives POTELIGEO 
4. Bivirkninger<br />
5. Opbevaring<br />
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What poteligeo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What poteligeo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>POTELIGEO indeholder det aktive stof mogamulizumab, der tilhører en gruppe lægemidler, som 
kaldes for monoklonale antistoffer. Mogamulizumab er rettet mod kræftceller, der efterfølgende 
ødelægges af immunsystemet (kroppens forsvarssystem). </p>
<p>Dette lægemiddel bruges til behandling af voksne med mycosis fungoides og Sézarys syndrom, som er 
nogle kræfttyper, der kaldes for kutane T-cellelymfomer.  Lægemidlet er beregnet til anvendelse til 
patienter, der har fået mindst ét lægemiddel indgivet gennem munden eller som en injektion. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take poteligeo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take poteligeo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke POTELIGEO 
- hvis du er allergisk over for mogamulizumab eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i afsnit 6).  </p>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller sygeplejersken, før du bruger POTELIGEO, hvis du:</p>
<ul>
<li>nogensinde har haft en alvorlig hudreaktion på grund af dette lægemiddel. </li>
<li>nogensinde har haft en infusionsreaktion på grund af dette lægemiddel (mulige symptomer på 
en infusionsreaktion er oplyst i afsnit 4).   </li>
<li>har human immundefektvirus (hiv), herpes, cytomegalovirus (CMV) eller hepatitis B- eller C-
infektion eller andre igangværende infektioner.  </li>
<li>har fået eller planlægger at få en stamcelletransplantation, enten med anvendelse af dine egne 
celler eller en donors celler.  </li>
<li>har haft tumorlysesyndrom (en komplikation, der indebærer ødelæggelse af kræftceller) efter en 
tidligere behandling. </li>
<li>har problemer med hjertet.   </li>
</ul>
<p>Fortæl det straks til den person, der giver dig infusionen, eller søg straks læge, hvis du får en 
reaktion under eller efter en infusion af POTELIGEO. </p>
<p>Fortæl det straks til lægen, hvis du får nogen af de alvorlige bivirkninger, der er anført i afsnit 
4, efter du er startet i behandling med POTELIGEO. </p>
<p>Brug af andre lægemidler sammen med POTELIGEO 
Fortæl lægen, hvis du tager andre lægemidler, for nylig har taget andre lægemidler eller planlægger at 
tage andre lægemidler. </p>
<p>Børn og unge 
Dette lægemiddel bør ikke anvendes til børn og unge under 18 år.  </p>
<p>Graviditet og amning 
Virkningerne af anvendelse af POTELIGEO under graviditet og amning er ikke kendte. På grund af 
lægemidlets virkningsmekanisme kan det skade barnet, hvis det gives, mens du er gravid eller ammer.  </p>
<p>Hvis du kan blive gravid, skal du bruge sikker prævention under behandlingen og i mindst 6 måneder 
efter behandlingen. </p>
<p>Hvis du ammer, skal du tale med din læge om, hvorvidt du kan amme under eller efter behandling med 
POTELIGEO.  </p>
<p>Fortæl det til lægen eller sygeplejersken, hvis du er gravid eller ammer, har mistanke om, at du er 
gravid, eller planlægger at blive gravid.  </p>
<p>Trafik- og arbejdssikkerhed 
Det er usandsynligt, at POTELIGEO vil påvirke din evne til at køre bil og betjene maskiner. Dette 
lægemiddel kan dog medføre træthed hos nogle mennesker, så vær særligt forsigtig i forbindelse med 
bilkørsel og betjening af maskiner, indtil du er sikker på, at lægemidlet ikke påvirker dig.  </p>
<p>POTELIGEO indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. hætteglas, dvs. det er i det 
væsentlige ‘natriumfrit’. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take poteligeo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take poteligeo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Den mængde POTELIGEO, du vil få, beregnes af lægen på baggrund af din legemsvægt.  Den 
anbefalede dosis er 1 mg POTELIGEO for hvert kilogram legemsvægt. </p>
<p>POTELIGEO vil blive indgivet gennem en blodåre (intravenøs infusion) i et tidsrum på mindst minutter. I starten vil infusionerne blive givet én gang om ugen for de første 5 doser og derefter én 
gang hver anden uge. Behandlingen bør fortsætte, medmindre du får en alvorlig bivirkning, eller det 
kutane T-cellelymfom begynder at blive værre.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige bivirkninger </p>
<p>Fortæl det til din læge eller sygeplejerske eller søg straks lægehjælp, hvis du får et eller flere af 
følgende tegn og symptomer, efter du er startet i behandling med POTELIGEO: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>kulderystelser, kvalme eller opkastning, hovedpine, hvæsende vejrtrækning, kløe, rødme, 
udslæt, svimmelhed eller mathed, vejrtrækningsbesvær og feber, som kan være tegn på en 
infusionsreaktion. Hvis det sker, skal infusionen muligvis afbrydes, og du kan have behov for 
yderligere behandling. POTELIGEO kan normalt gives igen, når symptomerne forsvinder, men 
blot i et langsommere tempo. Lægen kan standse behandlingen med POTELIGEO, hvis din 
reaktion er alvorlig.  </li>
<li>tegn på infektion, som kan være feber, svedtendens eller kulderystelser, influenzalignende 
symptomer, ondt i halsen eller synkebesvær, hoste, stakåndethed, mavesmerter, kvalme eller 
opkastning, diarré og svær utilpashed.  </li>
<li>
<p>hududslæt (som kan blive kraftigt) eller ømhed i munden. Hos nogle personer, der har fået 
POTELIGEO for andre typer kræft, forekom hudsmerter/brændende fornemmelse, kløe, 
hudblærer/afskalning, sår i munden eller på læberne eller kønsdelene, hvilket kan være tegn på 
en svær hudreaktion, for eksempel Stevens-Johnsons syndrom eller toksisk epidermal nekrolyse 
(der forekommer hos op til en 1 ud af 100 personer).<br />
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer):</p>
</li>
<li>
<p>feber, kulderystelser, kvalme, opkastning, forvirring, stakåndethed, krampeanfald, uregelmæssig 
hjerterytme, mørkfarvet eller grumset urin, usædvanlig træthed og/eller muskelsmerter eller 
ledsmerter. Ødelæggelsen af kræftceller og kroppens reaktion på dette kan i sjældne tilfælde 
føre til et problem, der kaldes for tumorlysesyndrom.brystsmerter, stakåndethed, hurtig eller 
langsom hjerterytme, svedtendens, svimmelhed, kvalme eller opkastning, svækkelse, mathed og 
utilpashed. Selvom det er usandsynligt, at det skyldes dette lægemiddel, kan disse symptomer 
være tegn på en hjertesygdom. 
Ikke kendt: Hyppighed kan ikke estimeres ud fra forhåndenværende data:</p>
</li>
<li>
<p>hvis du skal have en stamcelletransplantation, er det muligt, at du kan få komplikationer ("graft 
versus host disease"), som er svære at behandle. Symptomerne kan omfatte hududslæt eller 
blæredannelse i huden, kvalme eller diarré, der ikke forsvinder, mavesmerter eller opkastning, 
ledsmerter eller stive led, tørre eller irriterede øjne eller sløret syn, sår, irritation eller smerter i 
munden, hoste, der ikke forsvinder, eller vejtrækningsbesvær, følsomme kønsorganer, gulsot 
(gulfarvning af huden), mørkfarvet urin og eventuelt hævelse.  </p>
</li>
</ul>
<p>Andre bivirkninger </p>
<p>Fortæl det til lægen, hvis du får andre bivirkninger. Disse kan omfatte: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>Manglende energi (træthed) </li>
<li>Forstoppelse </li>
<li>Hævede ben eller ankler  </li>
<li>Hovedpine </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>Blodmangel (fald i antal røde blodlegemer) </li>
<li>Fald i antal blodplader (thrombocytopeni) </li>
<li>Fald i antal hvide blodlegemer (neutropeni og leukopeni) eller fald i antal lymfocytter </li>
<li>Blodprøver, der viser forhøjede niveauer af leverenzymer </li>
<li>Underaktiv skjoldbruskkirtel </li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer):</p>
<ul>
<li>Betændelse i leveren (hepatitis). </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store poteligeo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store poteligeo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og hætteglasset efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned.  </p>
<p>Uåbnet hætteglas: Opbevares i køleskab (2 ºC - 8 ºC). Må ikke nedfryses. </p>
<p>Opbevares i den originale karton for at beskytte mod lys. </p>
<p>Rekonstitueret/fortyndet opløsning: Bruges straks eller opbevares i køleskab (2 ºC - 8 ºC) og anvendes 
inden for 24 timer. </p>
<p>Brug ikke lægemidlet, hvis du bemærker tegn på nedbrydning, som f.eks. partikler eller misfarvning.  </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>POTELIGEO indeholder:</p>
<ul>
<li>Hvert hætteglas indeholder 20 mg mogamulizumab i 5 ml koncentrat svarende til 4 mg/ml. </li>
<li>Øvrige indholdsstoffer: citronsyremonohydrat, glycin, polysorbat 80, natriumhydroxid, saltsyre 
og vand til injektionsvæsker. Se afsnit 2 "POTELIGEO indeholder natrium". </li>
</ul>
<p>Udseende og pakningsstørrelser 
POTELIGEO er en klar, farveløs opløsning. Pakningen indeholder et hætteglas med 5 ml koncentrat 
til infusionsvæske, opløsning.  </p>
<p>Indehaver af markedsføringstilladelsen 
Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132 NP Hoofddorp 
Holland 
medinfo@kyowakirin.com </p>
<p>Fremstiller<br />
allphamed PHARBIL Arzneimittel GmbH 
Hildebrandstr. 10-37081 Göttingen 
Tyskland </p>
<p>Kyowa Kirin Holdings B.V. 
Bloemlaan 2 
2132 NP Hoofddorp 
Holland  </p>
<p>Denne indlægsseddel blev senest ændret &lt;{MM/ÅÅÅÅ}&gt;&lt;{måned ÅÅÅÅ}&gt;. </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-249170621fe2e34bc97c331b03b5b5b0
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for poteligeo Package Leaflet for language en"
Description: "ePI document Bundle for poteligeo Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-249170621fe2e34bc97c331b03b5b5b0"
* entry[0].resource = composition-en-249170621fe2e34bc97c331b03b5b5b0

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp249170621fe2e34bc97c331b03b5b5b0"
* entry[=].resource = mp249170621fe2e34bc97c331b03b5b5b0
                            
                    
Instance: bundlepackageleaflet-da-249170621fe2e34bc97c331b03b5b5b0
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for poteligeo Package Leaflet for language da"
Description: "ePI document Bundle for poteligeo Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-249170621fe2e34bc97c331b03b5b5b0"
* entry[0].resource = composition-da-249170621fe2e34bc97c331b03b5b5b0

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp249170621fe2e34bc97c331b03b5b5b0"
* entry[=].resource = mp249170621fe2e34bc97c331b03b5b5b0
                            
                    



Instance: mp249170621fe2e34bc97c331b03b5b5b0
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product POTELIGEO 4 mg/mL concentrate for solution for infusion"
Description: "POTELIGEO 4 mg/mL concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1335/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "POTELIGEO 4 mg/mL concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 249170621fe2e34bc97c331b03b5b5b0ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "poteligeo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with poteligeo"

* subject = Reference(mp7761089c74a9dfa81323fc8f18a36e0c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#poteligeo "poteligeo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-249170621fe2e34bc97c331b03b5b5b0) // poteligeo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-249170621fe2e34bc97c331b03b5b5b0) // poteligeo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-249170621fe2e34bc97c331b03b5b5b0
InstanceOf: List

* insert 249170621fe2e34bc97c331b03b5b5b0ListRuleset
    